The growth, which concerned an funding of CHF80m (USD99.8m), is about to considerably enhance Clariant’s manufacturing capabilities in one in every of its key development markets, notably China’s quickly evolving specialty chemical compounds sector.
Particularly, the newly opened amenities will enhance the corporate’s manufacturing capabilities in two predominant areas — pharmaceutical excipients, and specialty chemical compounds for private and residential care purposes.
This twin focus is geared toward assembly the rising high quality and efficiency expectations of Chinese language customers and industries, in addition to strengthening Clariant’s place as a number one provider of high-quality specialty chemical compounds in Asia.
“This funding represents a pivotal second for Clariant’s operations in China. With these expanded amenities, we at the moment are higher positioned to contribute to the well being and well-being of Chinese language customers whereas supporting the expansion of native industries with our modern specialty chemical compounds,” stated Christian Vang, Enterprise President of Care Chemical compounds at Clariant.
Nearer to clients
One of many new amenities at Daya Bay is a second spray tower particularly designed to serve clients in south China.
This raises manufacturing capability for each Lively Pharmaceutical Components (APIs) in laxatives and pharmaceutical excipients. With this, the power will serve Clariant’s healthcare enterprise, sustaining constant high quality requirements throughout China and worldwide.
Complementing the pharmaceutical growth, the corporate has additionally expanded their multi-purpose plant (MPP) at Daya Bay with a further reactor.
This facility is devoted to producing specialty chemical compounds, together with delicate surfactants for the wonder business and soil launch polymers for the house care sector beneath the Texcare vary.
These merchandise cater to the rising shopper demand for light but efficient private care merchandise and high-performance house care options.
As well as, the growth at Daya Bay has additionally considerably elevated the manufacturing capability for ethylene oxide derivatives (EODs) and a broader chemical portfolio.
“The evolution of Daya Bay from Clariant’s first ethoxylation plant in Asia to an built-in MPP and EOD website demonstrates our long-term imaginative and prescient for the area.
“By bringing our innovation and experience nearer to clients, we’re higher positioned to assist drive their developments ahead whereas addressing our clients’ sustainability targets and end-product efficiency wants.
“This growth not solely will increase our manufacturing capability, but in addition enhances our capability to collaborate intently with native clients on tailor-made options,” Vang stated.
He added that the corporate is now “higher outfitted than ever” to assist the innovation wants of its Chinese language clients throughout the pharmaceutical, private care, and residential care sectors.
